BioSpace News Archive

Tarsus Pharmaceuticals, Inc. announced that it has secured $200 million in committed capital from funds associated with Pharmakon Advisors, LP.

Artelo Biosciences, Inc. today announced the publication of an article, “The emerging role of fatty acid binding protein 7 (FABP7) in cancers,” in Drug Discovery Today, a peer-reviewed journal.

PaxMedica Inc., a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, expects to take immediate action in response to an urgent request for IV suramin from the Ministry of Health of Malawi, a country in east Africa.

Penumbra, Inc. announced the U.S. Food and Drug Administration clearance and launch of Lightning Flash™ 2.0, the next generation computer assisted vacuum thrombectomy system to remove venous thrombus and treat pulmonary emboli.

Centinel Spine®, LLC announced achievement of record revenue in the first quarter of 2024—outperforming Q4 2023, its previous record quarter.

Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, today announced its upcoming collaboration with Stanford Medicine’s Laboratory for Cell & Gene Medicine (LCGM) to demonstrate the potential of automation technology for cell therapy manufacturing.

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company

An automated tool that improves outbreak detection for hundreds of pathogens successfully served as an early warning system to find and respond to potential hospital outbreaks, as reported in NEJM Evidence.

Pillar Biosciences, Inc., the leader in Decision Medicine™ today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Premarket Approval (PMA) supplement application for its oncoReveal™ CDx pan-cancer solid tumor in vitro diagnostic (IVD).

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (“RT”), today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will present at the Planet MicroCap Showcase: VEGAS 2024, on Wednesday, May 1, 2024 at 4:30pm PT.